Magazine
As technology and psychedelics turn to mental health, we’ll likely see a future where we are treated based on our digital biomarkers, and sold mental health services based on the personal data we surrender.
Magazine
Psychedelic capitalists justify their decision to go for-profit in the ballroom of America’s most recent for-profit flop.
Magazine
After decades of psychedelic nonprofits paving regulatory pathways and priming wealthy investors, for-profits are moving in to reap the rewards.
Magazine
The new leaders of the psychedelic medicalization industry seem to see themselves as above their own self-proposed rules.
Magazine
“Play the field right and there’s money to be made even off some of the shit companies purely based on the wave.”
Magazine
Many predicted an ethical storm brewing in the lead-up to the explosion of for-profit interest in psychedelic pharmaceuticals. But, were their efforts to mitigate the damage enough to make a difference?
Podcasts
It’s not the Hokey Pokey, but psychedelic mainstreaming seems to be what it’s all about. We explore some of the realities and questions of what it means to take psychedelics “mainstream.”
Magazine
Can psychedelic civil disobedience really stimulate systemic reorganization?
Magazine
Our statement on a recent Chacruna article by Dr. Bia Labate.
Podcasts
We discuss our recent article, Lucy in the Sky with Nazis: Psychedelics and the Right Wing, which stirred up quite a bit of controversy. So to stir things up a little more, we’ve unpacked some of our perspectives while exploring questions of psychedelics as non-specific amplifiers of consciousness,
Magazine
Shlomi Raz, CEO of Eleusis Benefit Corporation, made false claims about psychedelics. We asked multiple ethnobotanists, a medical anthropologist, and a chemist if they could help us set the record straight.
Podcasts
Well, it’s official, psychedelics have entered the corporate-wellness mainstream. If you have any doubts, check out Gwyneth Paltrow’s new Netflix series, The Goop Lab. Or maybe don’t.